...Targeting NAD+ levels is a promising therapeutic strategy for heart failure. The translational potential is further enhanced by the fact that multiple compounds are available as NAD+ precursors or Nampt activators. Although no information is currently available on the pharmacokinetics or tolerability of these compounds in patients, similar information from healthy volunteers has been reported recently...It is also worth mentioning that all the preclinical studies reported so far used a “prevention” approach, i.e. the NAD+ pool was expanded at the same time as heart failure induction. For clinical application, it would be more appropriate to treat the subject when cardiac dysfunction has already developed. This type of study will advance our understanding for both mechanisms and efficacy in a scenario relevant for therapy, thus, critical for translation.